Current status of selegiline as a neuroprotective agent in Parkinson's disease

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 55-58

  Olanow, C Warren ^a   Mytilineou, Catherine ^a   Tatton, William ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; NEUROPROTECTIVE AGENT; SELEGILINE;

CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE;

EID: 0031946558     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Knoll J, Esceri Z, Kelemen K, et al. Phenyliopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155:154-164.
2. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology 1978;57:33-38.
3. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985;106:209-210.
4. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
5. Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984;311:467-469.
6. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
7. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: a long term study. J Neural Transm 1985;64:113-127.
8. Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO. Maintenance of l-deprenyl prolongs life in aged male rats. Life Sci 1990;47:415-420.
9. Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci 1989; 45:525-531.
10. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo M-C. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 1993;52:281-288.
11. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-522.
12. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46: 1052-1060.
13. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321: 1364-1371.
14. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
15. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991;42:13-26.
16. Schulzer M, Mak E, Calne DB. The anti-Parkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
17. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777.
18. Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995;91:177-182.
19. Elizan TS, Yahr MD, Moros DA, et al. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch Neurol 1989;46:1275-1279.
20. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
21. Parkinson Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
22. Parkinson's Study Group. The impact of extended deprenyl and tocopherol treatment in Parkinson's disease patients requiring levodopa. Ann Neurol 1996;39:29-36.
23. Parkinson's Study Group. The impact of extended deprenyl and tocopherol treatment in Parkinson's disease patients not requiring levodopa. Ann Neurol 1996;39:37-45.
24. Olanow CW. Selegiline: current perspectives on neuroprotection and mortality. Neurology 1996;47:210-216.
25. Lees A on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.
26. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality: a point of view. Ann Neurol 1996;40:841-845.
27. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity. J Neurochem 1997;68:33-39.
28. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochem 1985;45:1951-1953.
29. Roy E, Bedard PJ. L-deprenyl increases survival of rat fetal nigral neurones in culture. Neuroreport 1993;4:1183-1186.
30. Mytilineou C, Kototos Leonardi E, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. Journal of Pharmacology and Experimental Therapeutics. In press.
31. Buys YM, Trope GE, Tatton WG. (-)-deprenyl increases the survival of rat retinal ganglon cells after optic nerve crush. Curr Eye Res 1995;14:119-126.
32. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motoneurons by R(!)-L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053.
33. Salo PT, Tatton WG. L-deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992;31:394-400.
34. Zhang F, Richardson PM, Holland DP, Guo Q, Tatton WG. CNTF or (-)deprenyl in immature rats: survival of axotomized facial motor neurons and weight loss. J Neurosci Res 1995;40:564-570.
35. Chalmers-Redmond RME, Fraeser AD, Ju WYH, Wadia J, Tatton NA, Tatton WG. Mechanisms of nerve cell death: apoptosis or necrosis after cerebral ischemia. In: Green AR, Cross AJ, eds. Neuroprotective agents and cerebral ischemia. 1996:1-25.
36. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30:666-677.
37. Tatton WG, Ju WYL, Holland DP, et al. (-)-deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
38. Carrillo MC, Kanai M, Nokubo M, Kitani K. (-)-deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1990;48:517-521.
39. Carrillo MC, Kanai S, Nokubo M, Ivy GO, Sata Y, Kitani K. (-)-deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 1992;116: 286-294.
40. Carrillo MC, Kanai S, Sato Y, Ivy GO, Kitani K. Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats. Biochem Pharmacol 1992;44:2185-2189.
41. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)deprenyl-related compounds in controlling neurodegeneration. Neurology. In press.
42. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:202-220.
43. Wadia JS, Chalmers-Redman R, Ju WJH, Tatton WG. (-)deprenyl modifies pre-apoptotic changes in mitochondrial calcium and oxidative radicals in PC 12 cells. J Neurosci. In press.
44. Susin SA, Zamzami N, Kromer G. The cell biology of apoptosis; evidence for the implication of mitochondria. Apoptosis 1996;1: 231-242.
45. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. An antisense oligonucleotide to glyderaldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. Journal of Pharmacology and Experimental Therapeutics 1996;278:447-454.
46. +-induced apoptosis but not necrosis of cultured cerebellar granule cells. Mol Pharm 1997;51:542-550.